Table 1.

Types of delay or changes in planned care

Type of delay or change	Number of patients (%)
Delay in appointment
Delay in outpatient appointment (endocrinology or neurosurgery)	65 (15.8%)
Planned face to face appointment conducted via telephone	134 (32.5%)
Delay in investigations
Delay in pathology	200 (48.5%)
Delay in imaging	51 (12.4%) # *  • MRI pituitary: 27  • DEXA scan: 25  • TTE: 1
Delay in endocrine dynamic test	7 (1.7%) ##  • ITT: 4  • OGTT: 2  • GST: 1
Delay in treatment
Delay in pituitary radiotherapy	4 (1.0%)
Delay in pituitary surgery	2 (0.05%)
Difficulties obtaining prescribed endocrine medications	59 (14.3%) ###  • Testosterone or gonadotrophin 20  • Growth hormone:13  • Lanreotide: 4  • Hormone replacement therapy: 4  • Desmopressin: 2  • Cabergoline: 1  • Levothyroxine:1  • Denosumab: 1  • Prescription delays with local pharmacy or general practitioner: 15

^#MRI: Magnetic resonance imaging; DEXA scan: dual-energy X-ray absorptiometry; TTE: transthoracic echocardiogram (for a patient on cabergoline)

*2 patients had both an MRI and a DEXA scan delayed

^##ITT: insulin tolerance test; OGTT: oral glucose tolerance test; GST: glucagon stimulation test

^###1 patient had 3 medication issues